Management of patients with rheumatoid arthritis in real clinical practice: Switching from interleukin 6 receptor inhibitors to interleukin 6 inhibitor (olokizumab)

Management of patients with rheumatoid arthritis in real clinical practice: Switching from interleukin 6 receptor inhibitors to interleukin 6 inhibitor (olokizumab)

Aim. Switching to another biologic with the same mode of action provides greater opportunity for long-term management of patients with rheumatoid arthritis (RA). In clinical practice, especially in the context of the COVID-19 pandemic, such switching occurred for non-medical reasons as well. However...

Full description

Saved in:
Bibliographic Details
Main Authors: A. A. Baranov, I. B. Vinogradova, O. N. Anoshenkova, O. V. Antipova, E. A. Bogdanova, Y. Y. Grabovetskaya, E. P. Ilivanova, A. N. Kalyagin, I. N. Kushnir, N. A. Lapkina, M. V. Mokrousova, O. B. Nesmeyanova, N. M. Nikitina, P. A. Shesternya, N. V. Yudina, E. Feist, E. L. Nasonov
Format: Article
Language:Russian
Published: IMA PRESS LLC 2023-06-01
Series:Научно-практическая ревматология
Subjects:
rheumatoid arthritis
il-6 inhibitor
olokizumab
disease activity
outcomes
Online Access:https://rsp.mediar-press.net/rsp/article/view/3358
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://rsp.mediar-press.net/rsp/article/view/3358

Similar Items